214 related articles for article (PubMed ID: 22817659)
1. Invariant NKT cells increase drug-induced osteosarcoma cell death.
Fallarini S; Paoletti T; Orsi Battaglini N; Lombardi G
Br J Pharmacol; 2012 Dec; 167(7):1533-49. PubMed ID: 22817659
[TBL] [Abstract][Full Text] [Related]
2. CD1d expression and invariant natural killer T-cell numbers are reduced in patients with upper gastrointestinal cancers and are further impaired by commonly used chemotherapies.
Melo AM; Conroy MJ; Foley EK; Dockry É; Breen EP; Reynolds JV; Lysaght J; Doherty DG
Cancer Immunol Immunother; 2020 Jun; 69(6):969-982. PubMed ID: 32078695
[TBL] [Abstract][Full Text] [Related]
3. Fas/FasL interaction mediates imbalanced cytokine/cytotoxicity responses of iNKT cells against Jurkat cells.
Dou R; Hong Z; Tan X; Hu F; Ding Y; Wang W; Liang Z; Zhong R; Wu X; Weng X
Mol Immunol; 2018 Jul; 99():145-153. PubMed ID: 29783159
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/Fas-ligand pathway.
Duan X; Zhou Z; Jia SF; Colvin M; Lafleur EA; Kleinerman ES
Clin Cancer Res; 2004 Jan; 10(2):777-83. PubMed ID: 14760101
[TBL] [Abstract][Full Text] [Related]
5. CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.
Hara A; Koyama-Nasu R; Takami M; Toyoda T; Aoki T; Ihara F; Kobayashi M; Hirono S; Matsutani T; Nakayama T; Iwadate Y; Motohashi S
Cancer Immunol Immunother; 2021 May; 70(5):1239-1254. PubMed ID: 33128583
[TBL] [Abstract][Full Text] [Related]
6. Antibody-dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant natural killer T cells.
Mise N; Takami M; Suzuki A; Kamata T; Harada K; Hishiki T; Saito T; Terui K; Mitsunaga T; Nakata M; Ikeuchi T; Nakayama T; Yoshida H; Motohashi S
Cancer Sci; 2016 Mar; 107(3):233-41. PubMed ID: 26749374
[TBL] [Abstract][Full Text] [Related]
7. Thymosin alpha1 enhanced cytotoxicity of iNKT cells against colon cancer via upregulating CD1d expression.
Ni C; Wu P; Wu X; Zhang T; Zhang T; Wang Z; Zhang S; Qiu F; Huang J
Cancer Lett; 2015 Jan; 356(2 Pt B):579-88. PubMed ID: 25304368
[TBL] [Abstract][Full Text] [Related]
8. Utilization of invariant natural killer T cells for gastric cancer treatment.
Xu Q; Li J; Zhang N; Zhang L; Qian R
Future Oncol; 2018 Aug; 14(20):2053-2066. PubMed ID: 30051730
[TBL] [Abstract][Full Text] [Related]
9. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.
Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S
Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315
[TBL] [Abstract][Full Text] [Related]
10. Invariant NKT cells inhibit autoreactive B cells in a contact- and CD1d-dependent manner.
Yang JQ; Wen X; Kim PJ; Singh RR
J Immunol; 2011 Feb; 186(3):1512-20. PubMed ID: 21209282
[TBL] [Abstract][Full Text] [Related]
11. Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote
Jahnke S; Schmid H; Secker KA; Einhaus J; Duerr-Stoerzer S; Keppeler H; Schober-Melms I; Baur R; Schumm M; Handgretinger R; Bethge W; Kanz L; Schneidawind C; Schneidawind D
Front Immunol; 2019; 10():1542. PubMed ID: 31354710
[TBL] [Abstract][Full Text] [Related]
12. Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency.
Wingender G; Krebs P; Beutler B; Kronenberg M
J Immunol; 2010 Sep; 185(5):2721-9. PubMed ID: 20660713
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma.
Seki K; Yoshikawa H; Shiiki K; Hamada Y; Akamatsu N; Tasaka K
Cancer Chemother Pharmacol; 2000; 45(3):199-206. PubMed ID: 10663637
[TBL] [Abstract][Full Text] [Related]
14. Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control.
Guan P; Schaub R; Nichols KE; Das R
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708464
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
[TBL] [Abstract][Full Text] [Related]
16. Cancer Immunotherapeutic Potential of NKTT320, a Novel, Invariant, Natural Killer T Cell-Activating, Humanized Monoclonal Antibody.
Patel NP; Guan P; Bahal D; Hashem T; Scheuplein F; Schaub R; Nichols KE; Das R
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560408
[TBL] [Abstract][Full Text] [Related]
17. Critical role for invariant chain in CD1d-mediated selection and maturation of Vα14-invariant NKT cells.
Sillé FC; Martin C; Jayaraman P; Rothchild A; Besra GS; Behar SM; Boes M
Immunol Lett; 2011 Sep; 139(1-2):33-41. PubMed ID: 21565221
[TBL] [Abstract][Full Text] [Related]
18. CD1d-independent activation of invariant natural killer T cells by staphylococcal enterotoxin B through major histocompatibility complex class II/T cell receptor interaction results in acute lung injury.
Rieder SA; Nagarkatti P; Nagarkatti M
Infect Immun; 2011 Aug; 79(8):3141-8. PubMed ID: 21628519
[TBL] [Abstract][Full Text] [Related]
19. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.
Hayworth JL; Mazzuca DM; Maleki Vareki S; Welch I; McCormick JK; Haeryfar SM
Immunol Cell Biol; 2012 Aug; 90(7):699-709. PubMed ID: 22041925
[TBL] [Abstract][Full Text] [Related]
20. CD1d-dependent, iNKT-cell cytotoxicity against keratinocytes in allergic contact dermatitis.
Balato A; Zhao Y; Harberts E; Groleau P; Liu J; Fishelevich R; Gaspari AA
Exp Dermatol; 2012 Dec; 21(12):915-20. PubMed ID: 23171451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
